drugset / Trial / NCT02365506

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

NCT02365506

Phase 1 Completed 13 enrolled Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.

Timeline

Start
2015-07-20
Primary completion
2016-05-13
Completion
2016-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Eleclazine Small molecule 24 mg Oral
Subject Eleclazine Small molecule 48 mg Oral

Indications